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ALDH1A1 is a marker of both normal tissue and cancer stem cells, where it is involved in 
self-renewal, differentiation and self-protection. Few studies have examined the 
association between ALDH1A1 and mortality among breast cancer (BC) patients. None of 
these studies have included Hispanic women or explored interactions with alcohol 
consumption. We evaluated the associations between ALDH1A1 polymorphisms, alcohol 
consumption, and mortality among Hispanic and non-Hispanic white (NHW) BC cases 
from the Breast Cancer Health Disparities Study. 
 
Methods  
We evaluated the associations between nine SNPs of ALDH1A1 and mortality among 920 
Hispanic and 1372 NHW women diagnosed with incident invasive BC.  Demographic 
and lifestyle factors were collected via in-person interviews. Additive, recessive, and 
dominant models were considered for each SNP.  Cox proportional hazard regression 
models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs), 
adjusting for age at diagnosis, percentage of Native American (NA) ancestry, BC stage, 
and study site. Models were further stratified by percentage of NA ancestry and alcohol 





After a median follow-up time of 11 years from BC diagnosis, a total of 443 deaths 
occurred.  The following SNPs were associated with increased all-cause mortality risk:  
the CC genotype of rs1424482 (HRCC=1.31; 95% CI 1.03-1.68), the AA genotype of 
rs63319 (HRAA=1.29; 95% CI 1.05-1.59), and the AA genotype of rs7027604 
(HRAA=1.40; 95% CI 1.13-1.73). rs722921 (TA/AA vs. TT) (HRTA/AA=0.78; 95% CI 
0.64-0.95) decreased risk of all-cause mortality. Only rs7027604 remained significant 
after adjustment for multiple comparisons (Padj=0.018). Among ever drinkers, rs1888202 
decreased mortality risk (HRCG/GG=0.64; 95%CI 0.46-0.87), while no association was 
observed among non-drinkers (Pinteraction=0.022, Padj=0.181). Among women with low NA 
ancestry, rs63319 increased risk of mortality (HRAA=1.53; 95%CI 1.19-1.97), while a 
non-significant inverse association was observed among women of high NA ancestry 




We provide evidence that rs7027604 is significantly associated increased risk of 
mortality after BC. Future BC studies examining the relationship between ALDH1A1 and 
mortality should explore the modifying effects of alcohol consumption with rs1888202 
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Breast cancer is one of the most common cancers in women aged 45-64 in the United 
States. According to the American Cancer Society, in 2015, approximately 231,840 
females were diagnosed with breast cancer, among which about 40,290 died of the 
disease [1]. Breast cancer is a complex, multifactorial disease where there is a strong 
interplay between genetic (BRCA1 and BRCA2 [2]) and environmental factors (estrogen 
exposure [3], alcohol consumption [4], and dietary factors [5]). Furthermore, breast 
cancer is not a uniform disease, as in the U.S. alone, both incidence and mortality rates 
vary by time, geographic location, and by race and ethnicity. 
 
1. Racial/ethnic disparities in breast cancer prognosis 
1.1. The existence of racial/ethnic disparities 
There are marked differences in the U.S. for breast cancer incidence and mortality rates 
by race and ethnicity [6]: breast cancer mortality is greater in African-American women 
compared with white American women, despite an inverse pattern reported for breast 
cancer incidence. Five-year breast carcinoma survival rates are 86% for white American 
patients compared to only 71% for African-American patients [7]. Even with the 
implementation of mammographic screening for early detection, breast carcinoma 
mortality rates continue to rise among African-American patients, while rates have begun 
to decline among white Americans [7]. Summary statistics from a meta-analysis of 14 
studies revealed an odds ratio of 1.22 (95% confidence interval, 1.13–1.30) for the 
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adverse effect of African-American race on breast cancer mortality [8]. And the pooled 
all-cause mortality odds ratio was still significantly larger than 1 (1.27 with 95% 
confidence interval, 1.17-1.38) after adjusting for socioeconomic status (SES), indicating 
that African-American race was an independent predictor of mortality among women 
with breast cancer [8]. 
 
Similar results have been found among Hispanic women regarding breast cancer 
incidence and mortality rates [9-11]. Hispanic women also have higher mortality rates 
than non-Hispanic white (NHW) women, despite lower incidence rates [9, 10]. 
According to the results from a systematic review identifying several studies published 
between 1990 and 2007 [11], during the median follow-up period 6.3 years, the average 
incidence rates of Hispanic women was significantly lower than NHW women 
(IRRHispanic 0.70, 95% confidence interval, 0.57-0.85) after adjusting for age. However, 
the estimated five-year breast cancer survival probability for Hispanic women was much 
lower than NHW women: the survival rate for Hispanics at 0-5 years was 82% versus 
94% for NHWs, and the age-adjusted hazard ratios for Hispanic versus NHW was 3.4 
(95% confidence interval, 1.75-6.61) [10]. 
 
Both Hispanic and African-American women are more likely to be diagnosed at later 
stages of breast cancer compared to white American women [12, 13]. According to a 
recent meta-analysis using data from 17 population-based cancer registries in the 
Surveillance, Epidemiology, and End Results (SEER) program [13], compared to NHW 
women, Hispanic women had 1.4-, 1.8-, 1.5- fold higher odds of presenting with stage II, 
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III, IV tumors respectively, meanwhile African-American women also had significantly 
higher odds of presenting with more advanced stages of breast carcinomas. African-
American women along with Hispanic women had higher likelihood of being diagnosed 
with ER-/PR- breast cancer than NHWs (ORAA 2.4, 95% confidence interval, 2.3-2.5; 
ORHispanic 1.4, 95% confidence interval, 1.3-1.5); and among women with stage I or II 
breast carcinomas <2.0 cm in size, African-American women had an increased odds of 
receiving inappropriate primary surgical and radiation treatment (ORAA 1.5, 95% 
confidence interval, 1.3-1.6), and a similar situation was also found among Hispanic 
women (ORHispanic 1.2, 95% confidence interval, 1.1-1.3) [13]. In addition, both Hispanic 
and African-American female breast cancer patients tend to be younger [14]: among 
Hispanic and African-American patients, approximately 30% were diagnosed below age 
50 years and 12% were diagnosed above age 75 years, however, those proportions were 
18% and 21% respectively among NHW patients. Breast tumor sizes have also been 
reported to be different for Hispanic and African-American patients compared to NHW 
patients: Hispanic and African-American patients are more likely to have larger tumors 
(>3 cm) [10, 14]. 
 
1.2. Possible reasons for disparities 
Causes of inequities in breast cancer survival between minority (including African-
American and Hispanic) women and NHW women can be partially explained by the 
differences in the distribution of the modifiable and non-modifiable risk factors among 
these populations of women.  
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1.2.1. Clinical factors 
Previous research has shown that clinical factors such as age at diagnosis, breast cancer 
stage, tumor size, estrogen and progesterone negativity, and comorbid medical conditions 
can largely explain the disparities in breast cancer mortality among African-American 
women and NHW women [15]. Since African-American patients tended to be younger, 
have larger tumor size, diagnosed at later stage, more likely to be ER-/PR-, and had more 
comorbidity, thus they experienced worse prognosis of breast cancer than NHW patients 
[15]. The relevant studies with U.S. Hispanic women are sparse, but since the 
distributions of those clinical factors are similar among African-American and Hispanic 
patients, and both of them had higher mortality rates than white Americans, we 
hypothesize clinical factors are essential to explain the ethnic disparities in mortality 
between Hispanic and NHW women. 
 
1.2.2. Socioeconomic status (SES) 
SES has been found to play a prominent role in explaining racial disparities in breast 
cancer mortality. However, the effect of SES on racial disparities in mortality may differ 
as the stage of breast cancer at diagnosis changes. According to Parise’s research [16], for 
stage I patients, there was no significant difference between the risk of mortality among 
African-Americans and NHW within all SES strata; for stage II and stage III patients, 
African-Americans had the same risk of mortality as NHW in the lowest SES category 
but had an elevated risk of mortality in both intermediate and high SES groups; however, 
the hazard ratios for Hispanics versus NHW Americans were not significant regardless of 
disease stage and SES status [16]. Previous studies on how SES interplays with racial 
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disparities in breast cancer mortality have been inconsistent thus continued research is 
warranted. 
 
1.2.3. Germline mutations distribution and genetic testing 
Non-modifiable risk factors such as BRCA1 mutations were found to be associated with 
higher risk for triple negative breast cancer [17]. A previous study demonstrated that 
BRCA1 mutations were significantly more common in NHW women versus African-
American women, while BRCA2 mutations were more frequent in African-American 
women compared to NHW women [18]. Nevertheless, the frequency of BRCA1/2 
mutations were found to be dependent on the existence of family history of relevant 
cancers [19]. For those with family histories, NHW women had much higher prevalence 
of both BRCA1 and BRCA2 mutations than Hispanics and African-Americans; Hispanics 
had lower percentage of having BRCA2 and similar proportion of having BRCA1 
compared to African-Americans. However, for those without family histories, Hispanic 
Americans had the highest prevalence of BRCA1, followed by white Americans, while 
African-Americans had the lowest prevalence. Even though the advancements in genetic 
testing would help reduce the breast cancer associated morbidity and mortality, research 
suggest that African American women are significantly less likely to receive genetic 
counseling and testing compared to white women [19]. The similar studies with Hispanic 
women are limited. 
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1.2.4. Screening and follow-up for abnormal screening tests 
Access to breast cancer screening [20] and differences in quality of care among Hispanic, 
African-American and NHW women have also been found to contribute greatly to the 
disparities in breast cancer mortality [21]. Studies demonstrated significantly longer 
intervals for follow-up care after an abnormal mammogram for African-American 
women compared to white women, even after adjusting for insurance status [22]. 
 
1.2.5. Treatment 
Differences in treatment preferences and quality of treatment are also factors to explain 
racial disparities in breast cancer mortality. According to the literature, both African-
American and Hispanic patients were more likely to refuse having surgery and less likely 
to receive radiation therapy compared to the NHW patients [23]. Furthermore, only 69% 
of African-American patients received treatment within 30 days after diagnosis, while the 
proportion among NHW patients was 82% [22]. 
 
2. Breast cancer risk and prognostic factors 
2.1. Age  
Age is a well-documented risk factor affecting both incidence and mortality of breast 
cancer. According to Cancer Statistics 2015 [1], for women from age <50 years to ≥70 
years, for each 10 years increased category, the probability of developing invasive breast 
cancer gradually increased from 1.9% to 12.3%. On the other hand, studies also 
demonstrated that women ≤40 years of age at diagnosis had significantly greater breast 
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cancer mortality compared to older populations even after controlling for socio-
demographic factors, disease and treatment characteristics (HR 1.4, 95% confidence 
interval, 1.2-1.7) [24]. According to Partridge et al., the effect of age on survival of 
women with breast cancer was related to cancer subtypes: young age seems to be 
particularly prognostic in women with luminal breast cancers [24]. A Similar result was 
also found in another population-based study using the SEER 18 database [25], indicating 
that younger breast cancer patients exhibited more aggressive disease than older patients. 
The study also demonstrated that both young-aged (<40 years) and old-aged (≥60 years) 
patients had worse overall survival and breast cancer-specific survival compared to their 
middle-aged counterparts [25]. 
 
2.2. Reproductive factors 
Reproductive factors including parity, breastfeeding, age at first birth, age at menarche, 
and age at menopause are found to be associated with breast cancer risk and prognosis. 
Parity and breastfeeding are well-documented protective factors for breast carcinomas 
[26-28]. According to the systematic review [26], nulliparous women were at elevated 
risk for breast cancer compared to parous women, with relative risk ranging between 1.2 
and 1.7. The relationship between age at first birth and breast cancer risk is still 
controversial. Some studies found the older age at first birth, the higher risk of breast 
cancer [29], but the conclusions were not consistent. In a study conducted by Connor et 
al., researchers found that breastfeeding was a protective factor for both all-cause 
mortality and breast cancer-specific mortality among Hispanic and NHW women [27]. 
Kelsey’s systematic review [26] also provided evidence that the younger a woman’s age 
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Obesity is an important risk factor for developing postmenopausal breast cancer and also 
affects survival in women with breast cancer, but was found only among women that 
never used hormone replacement therapy (HRT) [30]. Among HRT non-users, heavier 
women (baseline BMI > 31.1) had an elevated risk of postmenopausal breast cancer (RR 
= 2.52; 95% CI 1.62–3.93) [30]. According to the meta-analysis conducted by Protani et 
al., which included 43 studies that enrolled women with breast cancer between 1963 and 
2005, the pooled hazards of overall mortality among obese women with breast cancer 
was significantly higher than the hazards of women with normal BMI (HR 1.33, 95% 
confidence interval, 1.21-1.47) [31]. Similar results were also found for risk of breast 
cancer-specific mortality (HR 1.33, 95% confidence interval, 1.19-1.50) [31]. 
 
2.4. Family history 
Family history of breast cancer has also been well documented as a significant predictor 
of both breast cancer risk and morality.   In an analysis of data from 52 epidemiologic 
studies [32], breast cancer risk was significantly elevated for women having first-degree 
relatives with breast cancer, and the relative risk (RR) also increased dramatically with 
adding number of first-degree relatives having the disease. The results indicated the RR 
for having 1 first-degree relative with breast cancer was 2.14 (95% confidence interval, 
1.92-2.38); for having 2 first-degree relative with breast cancer was 3.84 (95% 
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confidence interval, 2.37-6.22); and for having ≥3 first-degree relative with breast cancer 
was 12.05 (95% confidence interval, 1.70-85.16) [32]. Furthermore, the risk of breast 
cancer was higher among women with first-degree relatives who were diagnosed at 
younger ages compared to those diagnosed at older ages. Women with family history of 
breast cancer who were also diagnosed with breast cancer have also been found to have 
higher all-cause mortality than those without family history [32, 33]. 
 
2.5. Alcohol consumption 
Alcohol consumption has been identified as a risk factor for breast cancer in many 
epidemiological studies [34]. There has also been strong evidence of a dose-response 
relationship between alcohol consumption and breast cancer risk [35]: there was a 
monotonic rise in the RR of breast cancer with increase alcohol consumption, however 
the magnitude of the effect was small. Women having approximately one typical drink 
consumption per day had a RR of 1.10 (95% confidence interval, 1.06-1.14) to develop 
breast cancer compared to those nondrinkers [35]. Even though alcohol intake has been 
consistently and positively associated with risk of breast cancer in women [34-39], no 
significant results were observed in the studies examining the relationship between 
alcohol consumption and overall mortality after breast cancer diagnosis [37], except for 
one study showing that women who consumed 2-3 drinks per day had a higher risk of 
breast cancer mortality (RR 1.5, 95% confidence interval, 1.2-1.9), however the mortality 
did not increase for those having at least 4 drinks a day [38]. The complicated risk-benefit 
ratio of alcohol intake on breast cancer mortality might due to the protective effect of 
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moderate alcohol consumption on cardiovascular disease and overall mortality [39]. 
More relevant studies are needed. 
 
3. Aldehyde dehydrogenase 1A1 (ALDH1A1) gene 
ALDH1A1 is a marker of normal tissue stem cells and cancer stem cells, where it is 
involved in self-renewal, differentiation and self-protection [40]. Studies have shown that 
high expression of ALDH1A1 was correlated with poor cancer prognosis, including 
ovarian cancer [41], prostate cancer [42] and lung cancer [43]. However, the results were 
not consistent in other cancers: the result indicated that high expression of ALDH1A1 
was a prognostic marker for better survival in pancreatic cancer [44].  
 
How ALDH1A1 expression affects the survival of patients with breast cancer remains 
unclear and contradictory. Some studies demonstrated that high ALDH1A1 expression 
was associated with later stage breast cancer, larger tumor size, chemo-resistance, 
prediction for early metastasis, thus having poorer prognosis [45-48]. Specific SNPs of 
ALDH1A1 including rs8187996, rs3764435 and rs63319 were found to be significantly 
associated with grade 3 and 4 hematological toxicity among patients treated with 
cyclophosphamide and doxorubicin for breast cancer, which might contribute to poorer 
prognosis of breast cancer as well [49]. However, other research indicated ALDH1A1 
expression was independent to the prediction of breast cancer survival [50, 51], while one 
study reached an opposite conclusion reporting that high ALDH1A1 expression was 




4. ALDH1A1 gene and alcohol consumption 
ALDH1A1 is related to alcohol-induced flushing, alcohol sensitivity and dependence [53, 
54], and functions in the detoxification of acetaldehyde, the first metabolite of ethanol 
oxidation [55]. The association between genetic variation in ALDH1A1 and the 
vulnerability to alcohol dependence and other alcohol-related phenotypes has been 
investigated in some studies. According to the sequencing results from Spence and 
colleagues [53], two rare promoter polymorphisms, ALDH1A1*2 and ALDH1A1*3 
(which was only detected in African Americans) were sequenced. There was no 
association observed between ALDH1A1*2 and alcohol dependence, but there was a 
significant difference in ALDH1A1*3 allelic frequency between the alcoholics and the 
controls. Furthermore, the ALDH1A1*3 polymorphism resulted in reduced ALDH1A1 
expression. ALDH1A1*2 was found to be associated with alcohol dependence according 
to some similar research among different study populations including African-Americans 
and American Indians [56-58], nevertheless, the evidence on populations Hispanic and 
NHW is very sparse. 
 
5. Importance 
Few epidemiological studies have examined the association between ALDH1A1 and 
mortality among women with breast cancer.  To date, none of these studies have included 
Hispanic women or evaluated the modifying effect of alcohol consumption. These 
discrepancies and the scant body of literature in this research area highlight the need for 
more quantitative research to explore the underlying associations between ALDH1A1 
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polymorphisms, alcohol consumption, and mortality among Hispanic and NHW women 




Study design and population 
 
The Breast Cancer Health Disparities Study is comprised of participants from three 
population-based case-control studies: the 4-Corners Breast Cancer Study (4-CBCS), the 
San Francisco Bay Area Breast Cancer Study (SFBCS), and the Mexico Breast Cancer 
Study (MBCS) [59]. For this particular study, the study participants from the MBCS and 
all population-based controls were excluded due to missing data for vital status. 
Institutional Review Board for Human Subjects was obtained at each institution and 
informed consent was acquired from all participants before participation. Each participant 
completed an interview and had a mouthwash or blood sample for DNA extraction to 
access the genetic data. 
 
The 4-CBCS and the SFBCS have been described in detailed previously [59]. The 4-
CBCS consisted of NHW, Hispanic and Native American (NA) women participants aged 
25-79 years living in the areas of Arizona, Colorado, New Mexico, and Utah at the time 
of diagnosis or selection [60]. Cases were women histologically confirmed as either in 
situ or invasive breast cancer between October 1999 and May 2004. Controls were 
selected from the target populations and were frequently matched to cases on ethnicity 
and 5-year age distribution. A total of 2557 cases (1683 NHW, 852 Hispanics and 22 
American Indian) and 2605 controls (1669 NHW, 913 Hispanics and 23 American 
Indian) were included into the 4-CBCS [59]. Respondents who reported being NA 
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precluded separate analysis for this group, thus NA women and Hispanic women were 
grouped together in all of the 4-CBCS analyses [61]. The SFBCS comprised of NHW and 
Hispanic women aged 35-79 years from the San Francisco Bay Area [59]. The cases were 
women diagnosed with confirmed breast cancer between April 1995 and April 2002; and 
the controls were selected by random-digit dialing and frequency matched based on 
ethnicity and 5-year age distribution of cases. A total of 1105 cases (312 NHW and 793 
Hispanics) and 1318 controls (320 NHW and 998 Hispanics and) were included into the 
SFBCS [59]. 
 
For this study, the exclusion criteria were as follows: 1) all controls were excluded due to 
missing data pertaining to vital status and cause of death; 2) the cases that were not 
primary breast cancer; 3) the cases that were confirmed as in situ breast cancer; 4) the 
individuals whose cause of death was not specified; 5) had missing data for either 
percentage of NA ancestry or alcohol consumption. Our final study sample included a 




Data were harmonized across all study centers and questionnaires [59]. The main 
variables for harmonization were selected based on study hypotheses and the genetic 
pathways of interest. The current study considered adjusting for age at breast cancer 
diagnosis, percentage of NA ancestry (categorized as low ≤0.28 versus high >0.28), 
breast cancer summary stage (localized, regional, distant, or unstaged), and study site. 
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Long-term alcohol consumption was defined as the average amount of alcohol 
consumption in grams over specific ages (i.e. 15, 30 and 50). For the present analysis, 




DNA was extracted from either whole blood or mouthwash samples [62]. A total of 7286 
blood-derived and 637 mouthwash-derived samples were available for DNA analyses. 
Whole genome amplification was applied to the mouthwash-derived DNA samples prior 
to genotyping. A tagSNP approach was used to characterize variation across candidate 
genes. TagSNPs were selected using the following parameters: linkage disequilibrium 
(LD) blocks were defined using a Caucasian LD map and an 𝑟2 = 0.8; minor allele 
frequency >0.1; range = -1500 bps from the initiation codon to +1500 bps from the 
termination codon; and 1 SNP/LD bin [63]. 104 ancestral informative markers were used 
to distinguish European and NA ancestry in the study population. All markers were 
genotyped using a multiplexed bead array assay format based on GoldenGate chemistry 
(Illumina, San Diego, CA). A genotyping call rate of 99.93% was attained (99.65% for 
whole genome amplification samples). We included 132 internal replicates that were 
blinded representing 1.6% of the sample set. The duplicate concordance rate was 
99.996% as determined by 193,297 matching genotypes among sample pairs [59]. 
 
In the present study, we examined nine SNPs in the ALDH1A1 gene (rs348481, 
rs168351, rs1888202, rs63319, rs722921, rs348461, rs348463, rs7027604, rs1424482). 
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The ALDH1A1 polymorphisms in detail, including the minor allele frequencies (MAFs) 




Vital status was available for the Utah, New Mexico, Colorado, Arizona, and California 
study centers [63]. The cancer registry for each center provided information on the date 
of death or last date of follow-up [62]. Survival years were calculated as the date of death 
or last date of follow-up minus the date of diagnosis of breast cancer. For this analysis, 
causes of death were classified as breast cancer (death certificate noted breast cancer), 




The program STRUCTURE was used to compute individual ancestry for study 
participants assuming two founding populations [64, 65]. The level of percentage NA 
ancestry was used to classify each participant into either low or high percentage of NA 
ancestry group (≤0.28 versus >0.28). The descriptive statistics were calculated for all 
covariates and t-tests and chi-square tests were used to assess the differences between 
groups. The homozygous common genotypes for each SNP were used as the referent 
categories. Modes of inheritance including additive, dominant and recessive models were 
considered for each SNP accordingly using their genotypes. Haploview was used to 
check the linkage disequilibrium (LD) between the nine SNPs of ALDH1A1. We found 
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two blocks on this gene: the SNP rs348461 and rs348463, and the SNP rs7027604 and 
rs722921 were in high LD, respectively. Since the effects of the SNP rs7027604 and 
rs722921 on breast cancer mortality were in opposite direction, and neither of the SNP 
rs348461 nor rs348463 were significantly associated with all-cause mortality, we decided 
to keep all nine SNPs and analysis them separately before adjusting for multiple 
comparisons. Multivariate Cox proportional hazard regression models were used to 
calculate hazard ratios (HRs) and 95% confidence intervals (CIs). Proportional hazard 
assumption was checked by using Stata command estat phtest for each SNP. The 
proportional hazard assumption was met for all models. We evaluated potential 
confounders including age at diagnosis, percentage of NA ancestry, study sites, breast 
cancer summary stage, menopausal status, use of oral contraceptives, use of HRT, 
alcohol consumption and parity by calculating the percentage change in HRs for all-cause 
mortality (significant confounding defined by change in main effect point estimate of 
more than 10%). After this evaluation, we found that none of these factors were 
significantly confounding the associations between the SNPs and mortality outcomes; 
therefore we adjusted the final models for age at diagnosis, percentage of NA ancestry, 
breast cancer summary stage, and study site to account for any residual confounding by 
these factors. To detect effect modification, interaction terms were created between 
percentage of NA ancestry (low ≤0.28 versus high >0.28), alcohol consumption (ever 
versus never) and the polymorphisms. The likelihood ratio test was used to evaluate 
whether the interaction terms were significant. The Bonferroni correction was used to 
adjust for multiple comparisons [66]. 
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Power calculations were performed using the PS: Power and Sample Size Calculation 
version 3.0 software for the studies of survival analysis, which can be accessed at: 
http://biostat.mc.vanderbilt.edu/wiki/Main/PowerSampleSize [67, 68]. We estimated the 
power of the analysis using the SNPs rs168351 (having the lowest minor allele frequency 
which equals to 0.1171), rs722921 (having the highest minor allele frequency which 
equals to 0.4953) and rs7027604 (minor allele frequency equals to 0.4527). The 
following parameters were considered to calculate the power (refer to Table 3 and Table 
4): median survival time for patients in low NA ancestry group as 11 years, accrual time 
during which patients were recruited as 4 years, additional follow-up time after end of 
recruitment as 11 years, the number of patients who have minor allele as minor allele 
frequency of each SNP times total number of participants (0.1171*2292; 0.4953*2292; 









= 1.22) respectively, and defined 
type I error rate = 0.05, with HRs equal to 1.2, 1.5 and 2.0. Under the above conditions, 
the overall power ranged from 52.9% to 100.0% (Table 2). 
 
All statistical analyses were performed using SAS (version 9.2), Haploview (version 4.2) 






The baseline distributions of the genotype frequencies, demographics and major risk 
factors for breast cancer prognosis stratified by NA ancestry and alcohol consumption are 
shown in Table 3 and Table 4 respectively. A total of 2292 breast cancer cases were 
included in the present analysis, among which 1372 were in low NA ancestry category 
and 920 were in high NA ancestry category; the number of never-drinker was 1292 and 
the number of ever-drinker was 1000. After a median follow-up time of 11 years from 
breast cancer diagnosis, a total of 443 deaths occurred. The median survival time in low 
NA ancestry category was 10.83 years, which was statistically identical to the median 
survival time in high NA ancestry category (11 years). 
 
For low NA ancestry group versus high NA ancestry group (≤0.28 vs. >0.28), the 
distributions of the genotype frequencies were significantly different for some 
polymorphisms including rs1424482, rs168351, rs348461, rs368463, rs348481 and 
rs7027604. The distributions of the major risk factors for breast cancer prognosis such as 
age at diagnosis, cancer stage, menopausal status, oral contraceptives usage, HRT, parity, 
alcohol consumption, smoking pack years, BMI and median survival time were also 
compared between low and high NA ancestry groups (Table 3). Compared to women in 
low NA ancestry category, women in high NA ancestry group tended to have smaller 
proportion of being localized cancer (57.0% versus 67.7%), larger proportion of being 
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pre/peri-menopausal status (41.0% versus 34.3%), fewer cases using oral contraceptives 
(59.1% versus 71.2%) and HRT (42.2% versus 64.4%), and women in high NA ancestry 
group had significantly larger number of parities than women in low NA ancestry 
category. In addition, low NA ancestry group had significantly larger proportion of 
women ever had alcohol consumption compared to high NA ancestry group (52.1% 
versus 31.2%). The women in low NA ancestry group tended to be diagnosed at 
significantly older age than women in high NA ancestry group (55.61 versus 53.57 
years). The mean smoking pack year in low NA ancestry group was 8.73 with standard 
deviation 0.51, while the mean smoking pack year in high NA ancestry group was 2.97 
with standard deviation 0.30: the difference between the two groups was tremendous. 
Women in low NA ancestry category had smaller mean BMI than women in high NA 
ancestry group (27.4 versus 29.5 kg/m2). 
 
For never-drinker versus ever-drinker, the distributions of the genotype frequencies were 
statistically identical for all nine SNPs (Table 4). Compared to the distributions of the 
major risk factors for breast cancer prognosis, oral contraceptive usage, HRT, parity, 
smoking pack years and BMI were associated with alcohol consumption. Ever-drinkers 
were more likely to use oral contraceptives and HRT than never-drinkers, and they also 
tended to be less parous. The mean smoking pack year for ever-drinkers was 9.96 with 
standard deviation 0.65, which was significantly higher than that for never-drinkers (3.91 
with standard deviation 0.31), and ever-drinkers had lower average BMI than never-
drinkers (27.1 versus 29.2 kg/m2). The mean age was similar for never-drinkers and ever-
drinkers (54.71 versus 54.90 years). 
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Multivariate Cox proportional hazard model for overall mortality and breast 
cancer-specific mortality 
 
The results of the HRs, CIs and p-values from univariate and multivariate Cox 
proportional hazard models are shown in Table 5 and Table 8, for overall mortality and 
breast cancer-specific morality respectively. The following four SNPs were significantly 
associated with overall mortality:  rs1424482 (HRCC =1.31; 95% CI 1.03-1.68), rs63319 
(HRAA = 1.29; 95% CI 1.05-1.59), rs7027604 (HRAA = 1.40; 95% CI 1.13-1.73), and 
rs722921 (HRTA/AA = 0.78; 95% CI 0.64-0.95). However, only rs7027604 remained 
significant after adjustment for multiple comparisons (Padj = 0.018). Figure 1 shows the 
Kaplan-Meier survival curves for each genotype of the polymorphism rs7027604 taking 
into consideration the recessive mode of inheritance. The two survival curves for 
genotypes CC/CA and AA were significantly different (log rank p-value = 0.0043). 
 
For breast cancer-specific morality, the four SNPs that were significantly associated with 
overall mortality were also related to breast cancer-specific morality with the same 
directional point estimates: rs1424482 (HRCC =1.09; 95% CI 0.76-1.55), rs63319 (HRAA 
= 1.15; 95% CI 0.86-1.53), rs7027604 (HRAA = 1.21; 95% CI 0.90-1.63), and rs722921 




Associations between ALDH1A1 polymorphisms, all-cause and breast cancer-
specific mortality, stratified by alcohol consumption/NA ancestry 
 
The results of the stratification analyses and multivariate Cox proportional hazard 
regression models that included interaction terms created between alcohol consumption 
(ever versus never), level of NA ancestry (low versus high) and the SNPs for overall 
mortality are shown in Table 6 and Table 7, respectively. Among women with low 
percentage of NA ancestry (majority NHW women), rs63319 significantly increased risk 
of overall mortality (HRAA = 1.53; 95% CI 1.19-1.97), while a non-significant inverse 
association was observed among women of high percentage of NA ancestry (mostly 
Hispanic women) (HRAA = 0.92; 95% CI 0.64-1.34). Among ever drinkers, rs1888202 
significantly decreased risk of all-cause mortality (HRCG/GG = 0.64; 95%CI 0.46-0.87), 
while no association was observed among non-drinkers (HRCG/GG = 1.04; 95%CI 0.79-
1.36). However, the interaction terms for these two SNPs were not significant when 
conditioned on multiple comparisons. The results of the stratification analyses and 
multivariate Cox proportional hazard regression models that included interaction terms 
created between alcohol consumption (ever versus never), level of NA ancestry (low 
versus high) and the SNPs for breast cancer-specific mortality are shown in Table 9 and 
Table 10. Though the point estimates of hazard ratios were in the opposite direction 
between the different NA ancestry categories or alcohol consumption groups, we didn’t 





In this study that consisted of a large sample of Hispanic and NHW women from the 
Breast Cancer Health Disparities Study, we evaluated the associations of 9 
polymorphisms of ALDH1A1 with breast cancer-specific mortality and overall mortality 
after invasive breast cancer diagnosis. We observed that some polymorphisms of 
ALDH1A1, including rs1424482, rs63319, rs7027604 and rs722921 were significantly 
associated with worse breast cancer prognosis, conditioning on age at diagnosis, level of 
NA ancestry, disease stage, and study site. Taking into account multiple comparisons, 
rs7027604 was still statistically associated with worse breast cancer prognosis. When 
stratified by level of percentage NA ancestry (low versus high), we found rs63319 
significantly increased the risk of overall mortality among women with low percentage of 
NA ancestry, while a non-significant decrease in risk of all-cause mortality was observed 
among women in the high NA ancestry category. When stratified by alcohol consumption 
(ever versus never), rs1888202 significantly decreased the risk of mortality among ever 
drinkers, however no protective association was observed among never drinkers. If 
longer follow-up time permitted and more breast cancer cases were captured, we would 
expect the results to be similar for breast cancer-specific mortality. These findings 
support our hypotheses that polymorphisms from the ALDH1A1 gene are related to 
breast cancer prognosis, and these associations may be modified by level of NA ancestry 
and alcohol consumption. 
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Consistent with our findings, Ginestier et al. reported that ALDH1 is a marker of 
stem/progenitor cells of the normal human breast and breast carcinomas [45], and 
ALDH1-positive tumors were strongly associated with poorer clinical outcome compared 
to ALDH1-negative tumors: the 5 year overall survival was 69.59% (95% CI 60.73 – 
79.73) for patients with an ALDH1-positive tumors and 84.55% (95% CI 80.02 – 89.33) 
for patients with ALDH-negative tumors [45]. Zhong et al. studied the expression of 
ALDH1A1 in invasive breast carcinoma, where they pointed out that ALDH1A1 
expression was an independent predictor for recurrence-free survival and distant 
metastasis-free survival of breast cancer, and higher ALDH1A1 expression was 
associated with worse breast cancer prognosis [46]. The potential reasons to explain the 
association between higher ALDH1A1 expression and worse cancer prognosis include 
that the proportion of ALDH1-positive tumor cells together with CD44+/CD24- 
phenotypes were found to be significantly high when recurrence and metastasis occurred 
(P = 0.019) [47]; a positive relationship has also been found between ALDH1 expression 
and Ki-67 (a nuclear protein that is necessary for cellular proliferation) in invasive breast 
ductal carcinoma [46]; and that the metastasis, aggressive behaviors of breast cancer may 
be mediated by a cancer stem cells component that displays ALDH enzymatic activity 
[48]. 
 
The modifying effect of genetic ancestry on the association between ALDH1A1 
polymorphisms and breast cancer prognosis has not been studied, to date. There is one 
report illustrating how expression of ALDH1 acted as a marker to predict breast cancer 
prognosis in African women [69]. According to Schwartz et al., among African women, 
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of the ER-, PR-, and HER2- defined subtypes of breast cancer, expression of ALDH1 
was highest in triple-negative breast cancer, which has been found to be more aggressive 
and thus has a poorer prognosis compared to other subtypes of breast cancer due to its 
treatment complexities [69]. In our study, rs63319 significantly increased the risk of 
overall mortality among women with low percentage of NA ancestry (mostly NHW), 
while a non-statistically significant inverse association was observed with risk of all-
cause mortality among women of high percentage of NA ancestry (mostly self-reported 
Hispanics). The reasons to explain the modifying effect of NA ancestry percentage on the 
associations between ALDH1A1 polymorphisms and breast cancer prognosis could be 
that NHW women and Hispanic women are exposed to different mutagens or endogenous 
factors, resulting in different expression levels of the ALDH1A1 gene. It is also possible 
that the existence of other unmeasured or unidentified genetic variants in or near the 
ALDH1A1 gene could make a difference in our findings. Different allele frequencies in 
the promoter regions between two populations might indicate different transcriptional 
activities, which could influence the ethnic differences observed in our study. However, 
more relevant studies at both population level and molecular level are required in the 
future to reveal the underlying mechanism of how percentage of NA ancestry modifies 
the association between ALDH1A1 and all-cause mortality among breast cancer patients. 
Another study conducted by Liu et al. analyzing four independent populations illustrated 
that the associations between haplotype blocks across ALDH1A1 and alcohol 
dependence were significantly different among plains Indians, American Indians, Finnish 
Caucasians and African Americans [70]. If we take into consideration the study results by 
Liu et al. and our results, it could be inferred that there might be three way interactions 
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between ALDH1A1 polymorphisms, population stratification and alcohol dependence, 
providing directions for relevant studies in the future. 
 
To date, there are two papers that have demonstrated how ALDH1A1 is associated with 
alcohol-induced flushing, alcohol sensitivity and dependence [53, 54]. According to the 
sequencing results from Spence and colleagues [53], ALDH1A1*3 (one type of promoter 
polymorphism) was observed to have higher frequencies in the population of alcoholics, 
and ALDH1A1*3 expression was also found to be related to reduced ALDH1A1 
expression [53]. In combination with the literature mentioned previously [45-48], we 
hypothesized that alcohol consumption might be a protective factor against mortality for 
women with breast cancer, which was proven to be plausible according to our results. We 
found that among ever drinkers, rs1888202 significantly decreased risk of mortality 
(HRCG/GG = 0.64; 95%CI 0.46-0.87), while no association (HRCG/GG = 1.04; 95%CI 0.79-
1.36) was observed among non-drinkers. Consequently, alcohol consumption might have 
some modifying effect on the association between ALDH1A1 and mortality among 
women with breast cancer. 
 
The present analysis has several strengths and some limitations. Our study is one of the 
very few epidemiologic studies examining the association between ALDH1A1 and 
mortality among women with breast cancer within a diverse study population, including 
Hispanic and NHW women from various geographical areas. And to date, none of the 
studies have evaluated the modifying effect of either alcohol consumption and percentage 
of NA ancestry on this association. We not only compared the outcome of all-cause 
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mortality but also analyzed breast cancer-specific mortality. However, our study was 
limited by the sample size to consider breast cancer-specific mortality, as we were unable 
to capture more deaths in this study, resulting in lack of power in both multiple 
comparisons and breast cancer-specific mortality analyses. Additional follow-up time and 
larger sample size would be strengths for the breast cancer mortality analyses. We had 
missing values for the subtypes of breast cancer and breast cancer treatment, thus 
subtypes and treatment were not included into the models. However, we adjusted for 
breast cancer stage in the multivariate Cox proportional hazard regression models, which 
is a strong predictor for mortality. In addition, we did not model the recurrence of breast 
cancer in the analyses; the results might be enhanced or different if we include recurrent 
breast cancer cases into the model. Furthermore, the AIMs we used to control for 
population substructure may not be sufficient enough to capture all the ancestry data thus 
having residual confounding, nevertheless, the Breast Cancer Health Disparities Study 
(BCHDS) was designed and powered to address differences in breast cancer risk and 
prognosis based on these AIMs. The stratification analyses and interactions should be 
examined further in future studies with larger sample sizes. The association between 
ALDH1A1 and breast cancer-specific mortality should also be investigated with larger 
size of study populations and with more events of breast cancer-specific deaths in the 
future. 
 
In summary, our study provides evidence that rs7027604 is associated with worse 
prognosis after breast cancer diagnosis among Hispanic and NHW women.  Future breast 
cancer survival studies examining the relationship between ALDH1A1 and mortality 
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should also explore the modifying effects of genetic ancestry with rs63319 and alcohol 




Table 1. Description of ALDH1A1 polymorphisms by ethnicity, The Breast Cancer Health Disparities Study 
     Non-Hispanic White (NHW) Hispanic  
















rs1424482 9q21.13 75563557 INTRON  T/C 0.35 0.96 0.43 0.63 0 
rs168351 9q21.13 75517311 INTRON  A/G  0.17 0.86 0.07 0.12 0 
rs1888202 9q21.13 75519251 INTRON  C/G  0.49 0.93 0.49 0.70 0 
rs348461 9q21.13 75545070 INTRON  T/A  0.37 0.68 0.41 0.42 0.0005 
rs348463 9q21.13 75547612 INTRON  T/C  0.28 0.96 0.39 0.39 0.0005 
rs348481 9q21.13 75514436 INTERGENIC  T/C  0.23 0.49 0.12 0.10 0 
rs63319 9q21.13 75524784 INTRON  C/A  0.49 0.87 0.48 0.46 0.0005 
rs7027604 9q21.13 75554952 INTRON  C/A  0.42 0.96 0.48 0.82 0 
rs722921 9q21.13 75544299 INTRON  T/A  0.49 0.96 0.50 0.95 0 
          
*Major/minor allele reported for NHW population; minor allele frequency and Hard-Weinberg Equilibrium (HWE) based on control population. 
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Table 2. Power calculation using minor allele frequencies of the ALDH1A1 SNPs rs168351, 
rs722921 and rs7027604, The Breast Cancer Health Disparities Study 
 Hazard Ratios 
 1.2 1.5 2.0 
rs168351 (A/G)*    
Minor allele frequency = 0.1171 52.9% 99.1% 100.0% 
rs722921 (T/A)    
Minor allele frequency = 0.4953 88.5% 100.0% 100.0% 
rs7027604 (C/A)    
Minor allele frequency = 0.4527 88.2% 100.0% 100.0% 
* Major/minor allele 
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Table 3. Characteristics of study population, stratified by Native American (NA) ancestry, The 
Breast Cancer Health Disparities Study (N = 2292) 










rs1424482    <0.001* 
T/T 878 (38.3) 569 (41.5) 309 (33.6)  
T/C 1072 (46.8) 627 (45.7) 445 (48.4)  
C/C 342 (14.9) 176 (12.8) 166 (18.0)  
     
rs168351    <0.001* 
A/A 1757 (76.7) 960 (70.0) 797 (86.6)  
A/G 493 (21.5) 372 (27.1) 121 (13.2)  
G/G 42 (1.8) 40 (2.9) 2 (0.2)  
     
rs1888202    0.880 
C/C 588 (25.6) 357 (26.0) 231 (25.1)  
C/G 1,157 (50.5) 688 (50.2) 469 (50.9)  
G/G 547 (23.9) 327 (23.8) 220 (24.0)  
     
rs348461    0.042* 
T/T 850 (37.1) 528 (38.5) 322 (35.0)  
T/A 1085 (47.3) 650 (47.4) 435 (47.3)  
A/A 357 (15.6) 194 (14.1) 163 (17.7)  
     
rs348463    <0.001* 
T/T 1074 (46.8) 700 (51.0) 374 (40.7)  
T/C 978 (42.7) 565 (41.2) 413 (44.9)  
C/C 240 (10.5) 107 (7.8) 133 (14.4)  
     
rs348481    <0.001* 
T/T 1525 (66.5) 815 (59.4) 710 (77.2)  
T/C 684 (29.9) 484 (35.3) 200 (21.7)  
C/C 83 (3.6) 73 (5.3) 10 (1.1)  
     
rs63319    0.089 
C/C 571 (24.9) 331 (24.1) 240 (26.1)  
C/A 1135 (49.5) 668 (48.7) 467 (50.8)  
A/A 586 (25.6) 373 (27.2) 213 (23.1)  
     
rs7027604    0.032* 
C/C 719 (31.4) 456 (33.2) 263 (28.6)  
C/A 1100 (48.0) 651 (47.5) 449 (48.8)  
A/A 473 (20.6) 265 (19.3) 208 (22.6)  
     
rs722921    0.383 
T/T 606 (26.4) 371 (27.0) 235 (25.6)  
T/A 1113 (48.6) 650 (47.4) 463 (50.3)  
A/A 573 (25.0) 351 (25.6) 222 (24.1)  
     
Study Sites    <0.001* 
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4-Corners 1353 (59.0) 974 (71.0) 379 (41.2)  
SFBCS 939 (41.0) 398 (29.0) 541 (58.8)  
     
Stage of cancer    <0.001* 
Localized 1453 (63.4) 929 (67.7) 524 (57.0)  
Regional 732 (31.9) 398 (29.0) 334 (36.3)  
Distant 23 (1.0) 15 (1.1) 8 (0.9)  
Unstaged 84 (3.7) 30 (2.2) 54 (5.9)  
     
Menopause     0.002* 
Pre/Peri menopause 817 (37.0) 458 (34.3) 359 (41.0)  
Post menopause 1393 (63.0) 876 (65.7) 517 (59.0)  
     
Oral contraceptives    <0.001* 
Ever  1505 (66.3) 967 (71.2) 538 (59.1)  
Never 765 (33.7) 392 (28.8) 373 (40.9)  
     
HRT    <0.001* 
Ever 1076 (55.2) 736 (64.4) 340 (42.2)  
Never 872 (44.8) 407 (35.6) 465 (57.8)  
     
Parity     <0.001* 
Nulliparous 330 (14.4) 232 (16.9) 98 (10.65)  
1-2 953 (41.6) 616 (44.9) 337 (36.6)  
3-4 764 (33.3) 424 (30.9) 340 (37.0)  
≥5 245 (10.7) 100 (7.3) 145 (15.75)  
     
Alcohol consumption     <0.001* 
Ever  1002 (43.7) 715 (52.1) 287 (31.2)  
Never 1292 (56.3) 658 (47.9) 634 (68.8)  
     
Age at diagnosis    <0.001* 
Mean±SD 54.79±11.03 55.61±0.30 53.57±0.36  
     
Smoking (pack yrs)    <0.001* 
Mean±SD 6.40±14.01 8.73±0.51 2.97±0.30  
     
BMI (Kg/m2)    <0.001* 
Mean±SD 28.3±6.06 27.4±0.16 29.5±0.20  
     
Survival time    0.600 
Median 10.92 10.83 11  
     
¶ Percent of genetic admixture from NA ancestry (0 would be no NA ancestry and 1 would be only NA 
ancestry)
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Table 4. Characteristics of study population, stratified by alcohol consumption, The Breast 
Cancer Health Disparities Study (N = 2292) 
 Alcohol consumption  
SNPs/Covariates Overall 
(N = 2292) 
Never 
(n = 1292) 
Ever  
(n = 1000) 
P-value 
rs1424482    0.529 
T/T 878 (38.3) 482 (37.3) 396 (39.6)  
T/C 1072 (46.8) 613 (47.45) 459 (45.9)  
C/C 342 (14.9) 197 (15.25) 145 (14.5)  
     
rs168351    0.075 
A/A 1757 (76.7) 1011 (78.2) 746 (74.6)  
A/G 493 (21.5) 262 (20.3) 231 (23.1)  
G/G 42 (1.8) 19 (1.5) 23 (2.3)  
     
rs1888202    0.306 
C/C 588 (25.6) 347 (26.9) 241 (24.1)  
C/G 1,157 (50.5) 645 (49.9) 512 (51.2)  
G/G 547 (23.9) 300 (23.2) 247 (24.7)  
     
rs348461    0.354 
T/T 850 (37.1) 469 (36.3) 381 (38.1)  
T/A 1085 (47.3) 610 (47.2) 475 (47.5)  
A/A 357 (15.6) 213 (16.5) 144 (14.4)  
     
rs348463    0.158 
T/T 1074 (46.9) 583 (45.1) 491 (49.1)  
T/C 978 (42.7) 567 (43.9) 411 (41.1)  
C/C 240 (10.5) 142 (11.0) 98 (9.8)  
     
rs348481    0.064 
T/T 1525 (66.6) 875 (67.7) 650 (65.0)  
T/C 684 (29.8) 380 (29.4) 304 (30.4)  
C/C 83 (3.6) 37 (2.9) 46 (4.6)  
     
rs63319    0.730 
C/C 571 (24.9) 314 (24.3) 257 (24.7)  
C/A 1135 (49.5) 647 (50.1) 488 (48.8)  
A/A 586 (25.6) 331 (25.6) 255 (25.5)  
     
rs7027604    0.466 
C/C 719 (31.4) 392 (30.4) 327 (32.7)  
C/A 1100 (48.0) 627 (48.5) 473 (47.3)  
A/A 473 (20.6) 273 (21.1) 200 (20.0)  
     
rs722921    0.591 
T/T 606 (26.4) 352 (27.25) 254 (25.4)  
T/A 1113 (48.6) 623 (48.2) 490 (49.0)  
A/A 573 (25.0) 317 (24.55) 256 (25.6)  
     
Study Sites    0.208 
4-Corners 1353 (59.0) 748 (57.9) 605 (60.5)  
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SFBCS 939 (41.0) 544 (42.1) 395 (39.5)  
     
Stage of cancer    0.069 
Localized 1453 (63.4) 797 (61.7) 656 (65.6)  
Regional 732 (31.9) 424 (32.8) 308 (30.8)  
Distant 23 (1.0) 17 (1.3) 6 (0.6)  
Unstaged 84 (3.7) 54 (4.2) 30 (3.0)  
     
Menopause     0.729 
Pre/Peri menopause 817 (37.0) 466 (37.3) 351 (36.6)  
Post menopause 1393 (63.0) 784 (62.7) 609 (63.4)  
     
Oral contraceptives    <0.001* 
Ever  1505 (66.3) 780 (61.0) 725 (73.1)  
Never 765 (33.7) 498 (39.0) 267 (26.9)  
     
HRT    <0.001* 
Ever 1076 (55.2) 553 (50.6) 523 (61.1)  
Never 872 (44.8) 539 (49.4) 333 (38.9)  
     
Parity     <0.001* 
Nulliparous 330 (14.4) 148 (11.5) 182 (18.2)  
1-2 953 (41.6) 462 (35.8) 491 (49.1)  
3-4 764 (33.3) 494 (38.2) 270 (27.0)  
≥5 245 (10.7) 188 (14.5) 57 (5.7)  
     
Age at diagnosis    0.683 
Mean±SD 54.79±11.03 54.71±0.32 54.90±0.34  
     
Smoking (pack yrs)    <0.001* 
Mean±SD 6.40±14.01 3.91±0.31 9.96±0.65  
     
BMI (Kg/m2)    <0.001* 
Mean±SD 28.3±6.06 29.2±0.17 27.1±0.18  




Table 5. Univariate and multivariable Cox proportional hazard models for all-cause mortality, The Breast Cancer Health Disparities Study 
SNPs N No. death  HR§ P-value HR¶ P-value Padj £ 
rs1424482        
T/T or T/C 1950 364 1.00  1.00   
C/C 342 79 1.25 (0.98-1.60) 0.068 1.31 (1.03-1.68) 0.029* 0.233 
rs168351        
A/A 1757 345 1.00  1.00   
A/G 493 86 0.88 (0.69-1.11) 0.289 0.93 (0.73-1.19) 0.572 0.999 
G/G 42 12 1.49 (0.84-2.66) 0.172 1.51 (0.84-2.70) 0.168 0.809 
rs1888202        
C/C 588 128 1.00  1.00   
C/G or G/G 1704 315 0.82 (0.67-1.00) 0.055 0.85 (0.69-1.04) 0.113 0.660 
rs348461        
T/T 850 151 1.00  1.00   
T/A 1085 220 1.19 (0.97-1.46) 0.100 1.21 (0.98-1.49) 0.069 0.475 
A/A 357 72 1.15 (0.87-1.52) 0.330 1.24 (0.94-1.65) 0.129 0.712 
rs348463        
T/T 1074 197 1.00  1.00   
T/C 978 196 1.12 (0.92-1.37) 0.252 1.14 (0.93-1.39) 0.200 0.866 
C/C 240 50 1.14 (0.83-1.56) 0.397 1.24 (0.91-1.70) 0.175 0.823 
rs348481        
T/T 1525 302 1.00  1.00   
T/C 684 126 0.94 (0.76-1.15) 0.545 0.90 (0.73-1.11) 0.321 0.969 
C/C 83 15 0.91 (0.54-1.53) 0.718 0.91 (0.54-1.53) 0.717 0.999 
rs63319        
C/C or C/A 1706 314 1.00  1.00   
A/A 586 129 1.23 (1.00-1.51) 0.047* 1.29 (1.05-1.59) 0.015* 0.127 
rs7027604        
C/C or C/A 1819 329 1.00  1.00   
A/A 473 114 1.36 (1.10-1.69) 0.004* 1.40 (1.13-1.73) 0.002* 0.018* 
rs722921        
T/T 606 137 1.00  1.00   
T/A or A/A 1686 306 0.79 (0.64-0.96) 0.020* 0.78 (0.64-0.95) 0.015* 0.127 
§  Crude Cox Proportional Hazard model with only SNPs as covariate 
¶  Adjusted- Cox Proportional Hazard model adjusting for age at diagnosis, percentage of Native American (NA) ancestry, disease stage, and study site. 
£ Adjusted p-value using multiple comparison Bonferroni correction.  
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Table 6. Associations between ALDH1A1 polymorphisms and all-cause mortality, stratified by alcohol consumption, The Breast Cancer Health 
Disparities Study 
  Alcohol consumption   
Pinteraction 
 
Padj  Never  Ever 
 HR 95% CI P-value HR 95% CI P-value 
rs1424482       0.779 0.999 
T/T or T/C 1.00 -  1.00 -    
C/C 1.34 0.98 - 1.85 0.070 1.29 0.88 – 1.90 0.198   
rs168351       0.437 0.994 
A/A 1.00 -  1.00 -    
A/G 1.05 0.77 - 1.45 0.737 0.80 0.55 - 1.16 0.210   
G/G 1.59 0.70 - 3.63 0.268 1.40 0.61 - 3.19 0.427   
rs1888202       0.022* 0.181 
C/C 1.00 -  1.00 -    
C/G or G/G 1.04 0.79 - 1.36 0.801 0.64 0.46 - 0.87 0.005*   
rs348461       0.723 0.999 
T/T 1.00 -  1.00 -    
T/A 1.28 0.98- 1.68 0.071 1.11 0.80 - 1.53 0.549   
A/A 1.25 0.86 - 1.80 0.238 1.20 0.77 - 1.88 0.411   
rs348463       0.547 0.999 
T/T 1.00 -  1.00 -    
T/C 1.27 0.98 - 1.64 0.071 0.94 0.68 - 1.29 0.699   
C/C 1.20 0.79 - 1.82 0.402 1.30 0.81 - 2.09 0.278   
rs348481       0.481 0.997 
T/T 1.00 -  1.00 -    
T/C 0.93 0.71 - 1.23 0.615 0.86 0.62 - 1.19 0.365   
C/C 1.21 0.62 - 2.40 0.576 0.67 0.29 - 1.52 0.336   
rs63319       0.173 0.819 
C/C or C/A 1.00 -  1.00 -    
A/A 1.14 0.86 - 1.50 0.364 1.53 1.12 - 2.09 0.008*   
rs7027604       0.318 0.968 
C/C or C/A 1.00 -  1.00 -    
A/A 1.27 0.96 - 1.68 0.094 1.62 1.17 - 2.26 0.004*   
rs722921       0.356 0.981 
T/T 1.00 -  1.00 -    
T/A or A/A 0.85 0.65 - 1.10 0.215 0.69 0.51 - 0.95 0.023*   
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Table 7. Associations between ALDH1A1 polymorphisms and all-cause mortality, stratified by Native American (NA) ancestry, The Breast Cancer Health 
Disparities Study 
  Percentage (%) of NA Ancestry   
Pinteraction 
 
Padj  % NA Ancestry ≤ 0.28 % NA Ancestry > 0.28 
 HR 95% CI P-value HR 95% CI P-value 
rs1424482       0.642 0.999 
T/T or T/C 1.00 -  1.00 -    
C/C 1.40 1.01 – 1.93 0.041* 1.23 0.84 - 1.79 0.292   
rs168351       0.494 0.999 
A/A 1.00 -  1.00 -    
A/G 0.95 0.72 - 1.26 0.745 0.90 0.57 - 1.45 0.676   
G/G 1.55 0.86 - 2.78 0.143 - - -   
rs1888202       0.512 0.999 
C/C 1.00 -  1.00 -    
C/G or G/G 0.81 0.63-1.06 0.121 0.92 0.65 - 1.30 0.636   
rs348461       0.378 0.986 
T/T 1.00 -  1.00 -    
T/A 1.28 0.98 - 1.67 0.069 1.12 0.80 - 1.57 0.498   
A/A 1.39 0.97 - 2.00 0.076 1.08 0.69 - 1.69 0.732   
rs348463       0.318 0.968 
T/T 1.00 -  1.00 -    
T/C 1.17 0.91 - 1.51 0.209 1.10 0.79 - 1.52 0.584   
C/C 1.50 0.98 - 2.30 0.061 1.04 0.66 - 1.67 0.854   
rs348481       0.146 0.758 
T/T 1.00 -  1.00 -    
T/C 0.99 0.77-1.28 0.951 0.74 0.50 - 1.10 0.135   
C/C 0.99 0.57-1.71 0.975 0.54 0.07 - 3.87 0.537   
rs63319       0.022* 0.181 
C/C or C/A 1.00 -  1.00 -    
A/A 1.53 1.19 - 1.97 0.001* 0.92 0.64 - 1.34 0.676   
rs7027604       0.205 0.873 
C/C or C/A 1.00 -  1.00 -    
A/A 1.56 1.19 - 2.04 0.001* 1.18 0.83 - 1.67 0.357   
rs722921       0.397 0.990 
T/T 1.00 -  1.00 -    
T/A or A/A 0.73 0.57 - 0.95 0.017* 0.87 0.62 - 1.22 0.420   
 38 
Table 8. Univariate and multivariate Cox proportional hazard models for breast cancer-specific mortality, The Breast Cancer Health Disparities Study 
SNPs N No. death  HR§ P-value HR¶ P-value 
rs1424482       
T/T or T/C 1950 211 1.00  1.0  
C/C 342 36 0.98 (0.69-1.40) 0.923 1.09 (0.76-1.55) 0.648 
rs168351       
A/A 1757 198 1.00  1.00  
A/G 493 43 0.77 (0.55-1.06) 0.111 0.87 (0.62-1.22) 0.414 
G/G 42 6 1.30 (0.58-2.92) 0.530 1.66 (0.73-3.78) 0.229 
rs1888202       
C/C 588 65 1.00  1.00  
C/G or G/G 1704 182 0.94 (0.71-1.24) 0.646 0.95 (0.71-1.26) 0.707 
rs348461       
T/T 850 94 1.00  1.00  
T/A 1085 119 1.03 (0.78-1.35) 0.849 1.01 (0.77-1.32) 0.960 
A/A 357 34 0.87 (0.59-1.29) 0.487 0.97 (0.65-1.44) 0.875 
rs348463       
T/T 1074 112 1.00  1.00  
T/C 978 111 1.12 (0.86-1.45) 0.415 1.10 (0.84-1.43) 0.496 
C/C 240 24 0.96 (0.62-1.50) 0.868 1.03 (0.66-1.61) 0.903 
rs348481       
T/T 1525 173 1.00  1.00  
T/C 684 68 0.88 (0.66-1.16) 0.365 0.90 (0.68-1.19) 0.460 
C/C 83 6 0.63 (0.28-1.43) 0.273 0.73 (0.32-1.65) 0.445 
rs63319       
C/C or C/A 1706 184 1.00  1.00  
A/A 586 63 1.02 (0.77-1.36) 0.897 1.15 (0.86-1.53) 0.342 
rs7027604       
C/C or C/A 1819 189 1.00  1.00  
A/A 473 58 1.20 (0.89-1.61) 0.226 1.21 (0.90-1.63) 0.202 
rs722921       
T/T 606 69 1.00  1.00  
T/A or A/A 1686 178 0.91 (0.69-1.21) 0.523 0.89 (0.67-1.17) 0.403 
§  Crude Cox Proportional Hazard model with only SNPs as covariate 
¶  Adjusted- Cox Proportional Hazard model adjusting for age at diagnosis, percentage of Native American (NA) ancestry, disease stage, and study site. 
£ Adjusted p-value using multiple comparison Bonferroni correction.  
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Table 9. Associations between ALDH1A1 polymorphisms and breast cancer-specific mortality, stratified by alcohol consumption, The Breast Cancer 
Health Disparities Study 
  Alcohol consumption   
Pinteraction  Never  Ever 
 HR 95% CI P-value HR 95% CI P-value 
rs1424482       0.362 
T/T or T/C 1.00 -  1.00 -   
C/C 1.24 0.79 - 1.92 0.348 0.89 0.48 – 1.63 0.696  
rs168351       0.083 
A/A 1.00 -  1.00 -   
A/G 1.12 0.73 - 1.73 0.598 0.61 0.35 - 1.05 0.075  
G/G 2.26 0.81 – 6.32 0.118 0.99 0.24 - 4.06 0.985  
rs1888202       0.497 
C/C 1.00 -  1.00 -   
C/G or G/G 1.03 0.71 - 1.50 0.871 0.82 0.53 - 1.29 0.397  
rs348461       0.250 
T/T 1.00 -  1.00 -   
T/A 1.23 0.86 - 1.76 0.260 0.75 0.49 - 1.14 0.173  
A/A 1.07 0.64 - 1.79 0.798 0.84 0.45 - 1.56 0.576  
rs348463       0.214 
T/T 1.00 -  1.00 -   
T/C 1.32 0.94 - 1.87 0.113 0.81 0.53 - 1.24 0.332  
C/C 1.13 0.63 - 2.01 0.680 0.94 0.46 - 1.92 0.863  
rs348481       0.254 
T/T 1.00 -  1.00 -   
T/C 1.01 0.70 - 1.47 0.938 0.76 0.49 - 1.20 0.238  
C/C 1.01 0.37 - 2.78 0.980 0.46 0.11 - 1.89 0.282  
rs63319       0.597 
C/C or C/A 1.00 -  1.00 -   
A/A 1.06 0.72 - 1.56 0.757 1.28 0.83 - 1.97 0.271  
rs7027604       0.817 
C/C or C/A 1.00 -  1.00 -   
A/A 1.18 0.80 - 1.73 0.396 1.28 0.81 - 2.04 0.290  
rs722921       0.898 
T/T 1.00 -  1.00 -   
T/A or A/A 0.90 0.63 - 1.30 0.590 0.87 0.56 - 1.34 0.523  
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Table 10. Associations between ALDH1A1 polymorphisms and breast cancer-specific mortality, stratified by Native American (NA) ancestry, The Breast 
Cancer Health Disparities Study 
  Percentage (%) of NA Ancestry   
Pinteraction  % NA Ancestry ≤ 0.28¶ % NA Ancestry > 0.28 
 HR 95% CI P-value HR 95% CI P-value 
rs1424482       0.673 
T/T or T/C 1.00 -  1.00 -   
C/C 1.18 0.73 - 1.92 0.490 0.98 0.58 - 1.66 0.951  
rs168351       0.687 
A/A 1.00 -  1.00 -   
A/G 0.87 0.58 - 1.29 0.483 0.88 0.47 - 1.65 0.691  
G/G 1.81 0.79 – 4.14 0.163 - - -  
rs1888202       0.778 
C/C 1.00 -  1.00 -   
C/G or G/G 0.92 0.64-1.34 0.680 1.00 0.64 - 1.57 0.994  
rs348461       0.869 
T/T 1.00 -  1.00 -   
T/A 1.07 0.75 - 1.52 0.710 0.92 0.60 - 1.42 0.723  
A/A 0.96 0.55 - 1.69 0.898 0.97 0.55 - 1.71 0.903  
rs348463       0.487 
T/T 1.00 -  1.00 -   
T/C 1.13 0.81 - 1.59 0.480 1.05 0.69 - 1.60 0.824  
C/C 1.26 0.66 - 2.38 0.481 0.88 0.47 - 1.64 0.678  
rs348481       0.185 
T/T 1.00 -  1.00 -   
T/C 0.99 0.70-1.40 0.959 0.72 0.43 - 1.23 0.230  
C/C 0.95 0.41-2.18 0.904 - - -  
rs63319       0.460 
C/C or C/A 1.00 -  1.00 -   
A/A 1.25 0.87 - 1.81 0.222 0.98 0.61 - 1.57 0.930  
rs7027604       0.600 
C/C or C/A 1.00 -  1.00 -   
A/A 1.30 0.88 - 1.91 0.188 1.09 0.69 - 1.73 0.698  
rs722921       0.907 
T/T 1.00 -  1.00 -   







Figure 1. The Kaplan-Meier survival curves and log-rank test for genotype of the polymorphism 
rs7027604, taking into account the recessive mode of inheritance, The Breast Cancer Health 
Disparities Study 
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